Second versus first generation antipsychotics

According to a recently published study, there is no enough evidence supporting the idea that second generation antipsychotics (SGAs), which were developed to reduce the extrapyramidal symptoms associated to first generation antipsychotics (FGAs), offer any advantage over FGAs for the treatment of schizophrenia.

Data from 2003 in US, showed that three quarters of the 2 million adults with an antipsychotic prescription were taking SGAs, accounting for 93% of the annual $2.8 billion spent on such medicines.

After revising 114 studies, the conclusion was that there are no clinically important differences between different generation antipsychotics.

Be Sociable, Share!